Bryan’s practice focuses on complex commercial litigation and counseling, primarily in the antitrust area. A partner in the Firm’s Global Antitrust Practice based in New York, he represents clients in the pharmaceutical, financial services and petroleum sectors. Notable recent clients include Pfizer, Allergan, Boehringer Ingelheim, Experian, Novartis, OPEC and Warner Chilcott. Bryan’s knowledge and experience span a wide range of issues, including "reverse payment" settlements of patent disputes, product innovation and product retirement (so-called "product hopping"), price-fixing, fraudulent procurement of patents and other misconduct before the US Patent & Trademark Office, sham litigation, sham petitioning of the FDA, product bundling, and other antitrust theories. Bryan is a regular contributor to Antitrust Law Developments, and a member of the Antitrust Section of the American Bar Association.
1162 | Évènements
A Nov. 30 decision by the U.S. District Court for the District of Delaware, In re : Sensipar Antitrust Litigation, contradicts controlling U.S. Supreme Court precedent and, if followed, could have significant implications for patent settlements well outside the pharmaceutical context in which (...)
This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. On October 7, 2019, California became the first state to enact legislation— Assembly Bill 824 (“AB 824”)—rendering certain pharmaceutical patent litigation (...)
Classement de l'auteur